# Standard BioTools Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Standard BioTools Inc). ## Overview Standard BioTools Inc. develops and sells life-science tools used for proteomics and single-cell analysis, including instruments, consumables, assay kits, and related services. The company serves biopharmaceutical companies and academic research institutions, with operations centered in the United States and commercial reach into research markets outside the U.S. ## Products & services • Proteomics instruments • Consumables and assay kits • Lab services for protein biomarker analysis • Field services, maintenance, installation, and training • Collaborative R&D, license, grant, and royalty arrangements - **Instruments** (30%) — Proteomics and analytical instruments sold to research and biopharma customers. - **Consumables and assay kits** (35%) — Reagents, consumables, and SomaScan assay kits used with installed instruments. - **Lab services** (20%) — SomaScan assay services and biomarker data generation on customer samples. - **Field services** (10%) — Post-warranty service contracts, maintenance, installation, and training. - **Collaboration and other revenue** (5%) — R&D services, license agreements, grants, and royalties. - Proteomics instruments - Consumables and assay kits - Lab services for protein biomarker analysis - Field services, maintenance, installation, and training - Collaborative R&D, license, grant, and royalty arrangements ## Customers The company sells primarily to biopharmaceutical companies and academic research universities that need proteomics tools, assay capacity, and biomarker data. Its customer base also includes KOLs and other research collaborators that help validate and expand adoption of its platform. Demand is tied to research budgets, instrument placements, and the number of active assay sites using its consumables and services. - **Biopharmaceutical companies** (primary) — Buy instruments, consumables, and lab services for drug discovery, biomarker discovery, and translational research. - **Academic research universities** (primary) — Use proteomics assays and services for basic and translational research funded by grants and institutional budgets. - **KOLs and research collaborators** (secondary) — Partner on validation and platform expansion to support adoption and new market channels. - **Authorized assay sites** (primary) — Operate SomaScan assays and drive recurring kit and service usage through active testing volumes. - Biopharmaceutical companies buying proteomics tools and biomarker data - Academic research universities using assays for translational research - KOL collaborators helping validate and expand platform adoption - Authorized assay sites that consume kits and generate recurring usage - Customers needing installation, maintenance, and training support ## Geography The company is based in the United States and its disclosures indicate that its proteomic services are expected to expand beyond the U.S. over time. Its customer mix includes domestic and international research markets, with geography affecting procurement cycles, service delivery, and collaboration opportunities. No country-level revenue split was disclosed in the provided excerpts. - United States is the core operating and customer base - International research markets are a growth opportunity for services - Government- and grant-funded customers create seasonal demand patterns - Collaborations can open new regions where the company does not operate directly ## Strategy The company is focused on expanding its proteomics content, assay capabilities, and AI/ML analytics to deepen the value of its platform. It also emphasizes growing instrument placements and authorized sites, which support recurring consumables and service revenue and broaden customer adoption. Operationally, it is working to improve manufacturing efficiency and commercial execution while evaluating portfolio and transaction options. - **Expand proteomic content and assay capabilities** (medium-term) — A broader menu of reagents and panels strengthens the platform and supports more research use cases. - **Grow installed base and authorized sites** (short-term) — More instruments and sites drive recurring consumables, assay kits, and field services. - **Deepen data and analytics capabilities** (medium-term) — Proteomics databases and AI/ML analytics can improve differentiation and customer value. - **Improve manufacturing and operating efficiency** (short-term) — Lower unit costs and better execution support scalability and product competitiveness. - Expand proteomic content and assay panels - Grow instrument placements and authorized sites - Increase recurring consumables and service usage - Extend platform value through AI and machine learning analytics - Improve manufacturing efficiency and operating discipline - Use collaborations to open new channels and regions ## Risks The business depends on adoption of specialized proteomics products and services, so slower customer uptake or weaker research spending can affect demand. It also faces execution risk from manufacturing complexity, seasonal procurement patterns, and the need to keep expanding its scientific content and platform capabilities. Financial reporting is sensitive to goodwill and long-lived asset impairment judgments, especially when market capitalization weakens. - **Customer adoption and commercialization risk** [high] — Revenue depends on winning new contracts, expanding existing accounts, and growing instrument placements. - **Seasonality and budget-cycle dependence** [medium] — Government- and grant-funded customers often buy around fiscal year ends, creating quarter-to-quarter volatility. - **Manufacturing cost and supply risk** [high] — Product and service margins depend on raw materials, production yields, and capacity utilization. - **Goodwill impairment** [high] — A decline in market capitalization or weaker forecasts can trigger non-cash impairment charges. - **Divestiture and transaction execution risk** [high] — Portfolio changes or pending transactions can disrupt operations, employees, and customer relationships. - Customer adoption risk if research demand or platform uptake slows - Seasonality from grant and government budgeting cycles - Manufacturing and supply-chain complexity can affect product cost and availability - Goodwill and intangible asset impairment risk if market value weakens - Transaction and divestiture uncertainty can disrupt operations and attention ## Accounting Revenue is split across products, services, and collaboration-related arrangements, so timing and classification matter for comparability. The company also has meaningful judgment areas in inventory, warranty, and production variance costs, while seasonality can shift quarterly results. Goodwill and long-lived asset impairment testing is important because valuation assumptions can materially affect reported assets and earnings. - **Revenue recognition by stream** — Affects revenue timing and mix - **Seasonality** — Affects quarterly comparability - **Inventory and excess/obsolete reserves** — Affects cost of product revenue and gross margin - **Goodwill impairment** — Can create non-cash charges - Revenue classification across products, services, and collaborations - Seasonality affects quarter-to-quarter comparability - Inventory reserves and excess/obsolete stock provisions - Warranty and production variance costs in product margins - Goodwill and long-lived asset impairment judgments --- *Last updated: 2026-09-24T10:46:56.149590+00:00*